Welcome to our dedicated page for Propanc Bio news (Ticker: PPCB), a resource for investors and traders seeking the latest updates and insights on Propanc Bio stock.
Propanc Biopharma, Inc. develops proenzyme-based therapeutics for chronic diseases, including recurrent and metastatic cancer. Its lead asset, PRP, is an intravenous formulation of trypsinogen and chymotrypsinogen designed to target cancer stem cells, epithelial-mesenchymal transition, tumor angiogenesis, migration, and cancer cell death in solid tumors such as pancreatic and ovarian cancer.
Company news commonly covers PRP preclinical data, clinical-development preparations, pharmacokinetic assay work, GMP and trial-enabling activities, intellectual-property filings for proenzyme formulations and production methods, and research collaborations with the Universities of Jaén and Granada. Updates also include corporate financing, preferred-stock transactions, and periodic financial results.
Summary not available.
Summary not available.
Propanc Biopharma (OTC Pink: PPCB) announced breakthrough findings on PRP, its novel cancer treatment, demonstrating its ability to suppress the TGF-β pathway in pancreatic cancer. Research by Mrs. Belén Toledo Cutillas revealed that PRP effectively reduced tumor growth factors and inhibited chemoresistant tumor cells. Chief Scientific Officer Dr. Julian Kenyon emphasized PRP's potential as a chemosensitizing agent, potentially improving treatment outcomes for resistant solid tumors. PRP, derived from pancreatic proenzymes, shows promise in targeting various cancers without the typical side effects of standard therapies.
Propanc Biopharma, Inc. (OTC Pink: PPCB) announced findings regarding its proenzyme therapy, PRP, which shows significant effects against chemoresistant pancreatic tumor cells. Research conducted by Mrs. Belén Toledo Cutillas at the University of Jaén indicates that PRP downregulates chemoresistant gene expression in treated cells. Chief Scientific Officer Dr. Julian Kenyon emphasized that PRP alters the tumor microenvironment and could enhance clinical outcomes for pancreatic cancer patients. PRP, a mixture of two proenzymes, aims to prevent tumor recurrence and metastasis in various cancers.
Propanc Biopharma, Inc. (OTC Pink: PPCB) announced significant developments in cancer treatment at the 43rd EORTC PAMM meeting, where Mrs. Belén Toledo Cutillas presented novel strategies to disrupt tumor support systems. This approach aims to enhance drug efficacy against chemoresistant tumors. CEO James Nathanielsz emphasized PRP's prospective application as an adjunct therapy, targeting cancer stem cells. The global metastatic cancer market is forecasted at $111 Billion by 2027, highlighting the potential for Propanc's innovative research initiatives with Spanish universities.
Summary not available.
Propanc Biopharma, Inc. (OTC Pink: PPCB) announced insights from Chief Scientific Officer Dr. Julian Kenyon on their proenzyme therapy, PRP, which has potential as a chemosensitizer against pancreatic cancer. This condition has a poor prognosis, with a 5-year survival rate of under 8%. Dr. Kenyon emphasized PRP's unique ability to re-educate cancer-associated fibroblasts (CAFs) in the tumor microenvironment, potentially improving treatment outcomes. PRP consists of two pancreatic proenzymes and shows promise against multiple cancer types.
Propanc Biopharma (OTC Pink: PPCB) announced that its lead product candidate, PRP, may enhance the effectiveness of immune checkpoint inhibitors in treating pancreatic cancer. Chief Scientific Officer Dr. Julian Kenyon emphasized that PRP could expose tumors and reduce drug resistance. PRP has shown significant impact on tumor microenvironments by inhibiting tumor growth and promoting differentiation. The mixture of pancreatic proenzymes is administered intravenously and has potential implications for other treatment modalities.
Propanc Biopharma (OTC Pink: PPCB) announced that CEO James Nathanielsz will present at the Sidoti & Company Micro-Cap Virtual Investor Conference on November 9, 2022. He will discuss the developments of Propanc's lead product candidate, PRP, aimed at treating metastatic cancer by targeting cancer stem cells. PRP, a blend of pancreatic proenzymes administered intravenously, shows promise against various cancers including kidney and ovarian. This presentation reflects growing institutional investor interest in innovative healthcare solutions.
Propanc Biopharma, Inc. (OTC Pink: PPCB) announced participation in the 43rd EORTC-PAMM meeting in location value="LU/it..flonce"Florence, Italy from December 15 to 17. CEO James Nathanielsz and Lead Researcher Professor Macarena Perán will present findings on PRP, focusing on its anti-cancer properties targeting metastatic tumors. The research aims to develop non-toxic therapies to combat solid tumor recurrence. The EORTC aims to enhance cancer treatment and quality of life through innovative drug strategies.